Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Monte Rosa Therapeutics (NASDAQ: GLUE) has priced its initial public offering (IPO) of 11,700,000 shares of common stock at $19.00 per share, aiming for gross proceeds of approximately $222.3 million before expenses. The shares will begin trading on the Nasdaq Global Select Market on June 24, 2021, with the offering expected to close on June 28, 2021, subject to customary conditions. The underwriters have an option to purchase an additional 1,755,000 shares.